Somatuline Depot Injection
Product Images NDC 15054-1060

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Somatuline Depot (NDC 15054-1060). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ipsen Biopharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Somatuline 01)

Chemical structure diagram of lanreotide acetate showing the peptide sequence and associated groups as labeled in the image.*

FDA Label Image

Figure 1 (Somatuline 02)

A Kaplan-Meier curve showing progression-free survival probability (%) over time in months for patients treated with Somatuline Depot versus placebo. The graph includes survival probability trends for both groups and a table of the number of subjects still at risk at various time points. Hazard ratio, confidence interval, and p-value are also shown.*

FDA Label Image

Figure (Somatuline 03)

An instructional diagram illustrating inspection steps for SOMATULINE DEPOT injection packaging. It highlights checking that the box does not appear damaged and verifying the expiration date has not passed, focusing on proper packaging condition before use.*

FDA Label Image

Figure (Somatuline 04)

Instructional diagram illustrating the Somatuline Depot injection label, highlighting the available dose strengths as prescribed: 60 mg, 90 mg, or 120 mg. The image focuses on the packaging and dose selection options for the lanreotide acetate subcutaneous injection by Ipsen Biopharmaceuticals, Inc.*

FDA Label Image

Figure (Somatuline 05)

The image shows a carton of SOMATULINE DEPOT 60 mg subcutaneous injection by Ipsen Biopharmaceuticals, Inc., placed inside a refrigerator shelf next to a carton labeled SKIM MILK. The SOMATULINE DEPOT packaging is white with the strength and dosage form visible on the front.*

FDA Label Image

Figure (Somatuline 07)

An illustration of a calendar page showing the date August 29 with hourly lines from 9 AM to 2 PM. This likely represents a reminder or scheduling element related to medication dosing or administration timing.*

FDA Label Image

Figure (Somatuline 08)

SOMATULINE DEPOT 60 mg/.2 mL injection carton label for lanreotide acetate in subcutaneous form. The box is predominantly white with black text, showing the product name, strength, and dosage. The label also notes the manufacturer, Ipsen Biopharmaceuticals, Inc.*

FDA Label Image

Figure (Somatuline 09)

An instructional illustration showing an hourglass symbol with the text "30 min.", depicting a recommended 30-minute waiting or preparation time, over a packaged syringe labeled with the product name. This figure likely relates to the preparation or administration timing of the SOMATULINE DEPOT injection.*

FDA Label Image

Figure (Somatuline 10)

An instructional illustration showing a person lying face down on a surface, demonstrating the recommended position for a medical procedure or injection. The diagram includes the word 'OK' near the person's lower back and the text 'Lying down' below the image.*

FDA Label Image

Figure (Somatuline 11)

An illustration showing the recommended subcutaneous injection sites for SOMATULINE DEPOT, indicating the outer upper quadrants of the buttocks as appropriate areas for administration when standing.*

FDA Label Image

Figure (Somatuline 12)

An instructional illustration showing a hand gently holding and gathering a cluster of small spherical objects, positioned near the neck area of a human figure outline. The image likely demonstrates a technique or action related to the administration or handling of the medication.*

FDA Label Image

Figure (Somatuline 13)

Illustration showing two hands peeling back the sealing of a small foil pouch, likely demonstrating how to open a unit-dose package for injection.*

FDA Label Image

Somatuline 13a

Illustration showing the components of a SOMATULINE DEPOT pre-filled syringe, including the tray, needle cap, syringe body, and expiration date and dose label. The syringe is designed for subcutaneous injection of lanreotide acetate.*

FDA Label Image

Figure (Somatuline 14)

An instructional illustration showing a close-up view of a subcutaneous injection device for SOMATULINE DEPOT (lanreotide acetate). The image highlights the injection mechanism, including a labeled section with dosage and administration details, intended for correct subcutaneous delivery.*

FDA Label Image

Figure (Somatuline 15)

An instructional diagram showing the recommended subcutaneous injection sites for lanreotide acetate (SOMATULINE DEPOT). The image illustrates the lower abdominal area with marked injection sites on the left (L) and right (R) sides, each labeled 'OK' to indicate acceptable locations.*

FDA Label Image

Figure (Somatuline 16)

An instructional illustration depicting a hand applying a cloth or wipe to the buttock area, likely showing preparation or cleaning of the injection site for a subcutaneous injection.*

FDA Label Image

Figure (Somatuline 17)

An instructional line drawing showing a hand preparing an injection device by inserting a syringe into a prefilled applicator. This image demonstrates the step of assembling the device for subcutaneous injection.*

FDA Label Image

Figure (Somatuline 18)

Instructional illustration showing hands preparing a SOMATULINE DEPOT lanreotide acetate injection by removing the needle cap from a prefilled syringe before subcutaneous administration.*

FDA Label Image

Figure (Somatuline 19)

An instructional illustration showing a hand holding a syringe-style injector device. The syringe is depicted in a horizontal position with the thumb positioned to press the plunger, indicating the method for administering the injection. The device features measurement markings along the barrel and finger grips near the plunger.*

FDA Label Image

Figure (Somatuline 20)

An instructional illustration showing a hand pinching a fold of skin on the upper arm, indicating the preparation area for a subcutaneous injection. A label marked 'OK' highlights the appropriate injection site location for administration.*

FDA Label Image

Somatuline 20a

Instructional illustration showing a person's lower back and buttocks area with a hand placing an injection, crossed out by an X, indicating an injection site not to use. This image relates to subcutaneous injection guidance for SOMATULINE DEPOT (lanreotide acetate).*

FDA Label Image

Figure (Somatuline 21)

Illustration showing the proper technique to inject SOMATULINE DEPOT using a syringe at a 90-degree angle to the skin surface for subcutaneous administration. The image focuses on hand positioning and syringe orientation during injection.*

FDA Label Image

Figure (Somatuline 22)

Instructional diagram showing correct and incorrect hand positioning for using a subcutaneous injection device. The first panel with an X indicates an incorrect grip, while the second panel with a checkmark shows the proper way to hold and use the injection pen against the skin.*

FDA Label Image

Figure (Somatuline 23)

An instructional illustration showing a hand administering a subcutaneous injection into the upper buttock area. The syringe is positioned at a 90-degree angle to the skin. This image is likely part of injection guidance for the drug SOMATULINE DEPOT (lanreotide acetate).*

FDA Label Image

Figure (Somatuline 24)

An instructional illustration showing a hand holding the SOMATULINE DEPOT injection device, positioned for subcutaneous administration. The image includes an arrow indicating the direction for activating or pressing the device during the injection procedure.*

FDA Label Image

Somatuline 24a

An instructional diagram resembling a clock face illustrating a 20-second duration, with a shaded segment indicating the passage of time. The image is used for timing guidance related to the administration of an injection.*

FDA Label Image

Figure (Somatuline 25)

An instructional illustration showing a hand holding and preparing to use a SOMATULINE DEPOT injection device, designed for subcutaneous administration of lanreotide acetate. The image emphasizes proper grip and positioning for injection.*

FDA Label Image

Figure (Somatuline 26)

An instructional diagram illustrating the steps for preparing and using the SOMATULINE DEPOT injection device. The three-step sequence shows hand positioning and movement for activating and administering the subcutaneous injection of lanreotide acetate.*

FDA Label Image

Figure (Somatuline 27)

An instructional illustration showing the application of a patch or injection site preparation on the upper buttock area. The image depicts a hand pressing a pad or patch onto the skin, suggesting site cleaning or care prior to subcutaneous administration.*

FDA Label Image

Figure (Somatuline 28)

An instructional line drawing depicting a hand holding a syringe and disposing of it into a sharps disposal container. The image illustrates proper disposal of the injection device likely associated with subcutaneous administration, relevant to somatuline depot or similar injection products.*

FDA Label Image

Figure (Somatuline 29)

An instructional illustration showing hands holding small spherical pellets or beads over a container with liquid being poured from a bottle. This likely depicts how to mix or prepare the medication before administration.*

FDA Label Image

Principal Display Panel (60 mg/0.2 mL Syringe Carton)

Carton packaging for Somatuline Depot (lanreotide) Injection 60 mg/0.2 mL by Ipsen Biopharmaceuticals, Inc. The label shows it is for a single pre-filled syringe intended for deep subcutaneous injection. Storage instructions specify refrigeration at 2°C to 8°C and protection from light. The product is distributed by Ipsen Biopharmaceuticals, Cambridge, MA, USA, and manufactured by Ipsen Pharma Biotech, France.*

FDA Label Image

Principal Display Panel (90 mg/0.3 mL Syringe Carton)

Packaging label for SOMATULINE DEPOT injection containing lanreotide acetate 90 mg/0.3 mL, a subcutaneous injection. The label displays the Ipsen logo and indicates the product is for prescription use only. It includes storage instructions to refrigerate at 2°C to 8°C and advises leaving the syringe at room temperature for 30 minutes before administration. Distributed by Ipsen Biopharmaceuticals, Inc., Cambridge, MA.*

FDA Label Image

Principal Display Panel (120 mg/0.5 mL Syringe Carton)

Carton packaging label for Somatuline Depot (lanreotide) Injection 120 mg/0.5 mL, a subcutaneous injection. The label shows the product name, strength, and dosage form, with storage instructions advising refrigeration at 2°C to 8°C. Manufactured by Ipsen Pharma Biotech, France and distributed by Ipsen Biopharmaceuticals Inc., USA. The box contains one pre-filled syringe for single use and directs healthcare professional administration.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.